THE CORRELATION BETWEEN GALECTIN-3, CREATININE AND URIC ACID ON STAGE V CHRONIC RENAL FAILURE
DOI:
https://doi.org/10.24293/ijcpml.v25i1.1516Keywords:
Galectin-3, creatinine, uric acid, chronic renal failure, hemodialysisAbstract
Chronic Renal Failure (CRF) is structural damage and function of the kidneys that cannot excrete toxins and waste products from the blood, characterized by the presence of protein in the urine and decreased glomerulus filtration rate. This study aimed to determine the correlation between Galectin-3 and markers of kidney function which are creatinine and uric acid. This study was being concluded on 33 CRF patients who were doing hemodialysis therapy. This study was conducted in the Dr. Kariadi Semarang Hospital and GAKI Laboratory of Diponegoro Medical Faculty from April to June 2018. The research method was analytical descriptive with cross-sectional approach. Galectin-3 was analyzed using ELISA method with an automatic analyzer, creatinine and uric acid using the colorimetric method with an automatic spectrophotometer. Statistical analysis used Shaphiro-Wilk normality test and Spearman correlation test. There is a weak positive correlation test of galectin-3 with creatinine (r = 0.381; p = 0.029) and galectin-3 with uric acid (r = 0.374; p = 0.048) in CRF – HD. It is concluded galectin-3 can be used as a marker of kidney function.Downloads
References
. Pranandari R, Supadmi W.Faktor risikogagalginjalkronik di unit hemodialisis RSUD Wates Kulon Progo. Majalah Farmaseutik, UGM, 2015; 11(2): 316-20.
Robinson BE. Epidemiology of chronic kidney disease and anemia. JAMDA, 2006; 7(9): S3-6.
Suwitra K. Penyakit ginjal kronik. Dalam Sudoyo AW, Setiyohadi B, Idrus A. Editors: Buku ajar ilmu penyakit dalam. Jilid II, Edisi V., Jakarta, Interna Publishing, 2009; 1035-40.
Prodjosudjadi W, Suhardjono, Suwitra K. Detection and prevention of chronic kidney disease in Indonesia: Initial community screening. Nephrology, 2009; 14(7): 669-74.
Prodjosudjadi W, Suhardjono A. End-stage renal disease in Indonesia: Treatment development. Ethn Dis. 2009; 9(1): S1-33-6.
Li L-C, Jun L, Jian G. Function of galectin-3 and role in fibrotic disease. J Pharmacol Exp Ther, 2014; 351(2): 336-43.
Drechsler C, Graciela D, Christoph W, Katja B, Stefan P, Andreas T, et al. Galectin-3, renal function, and clinical outcomes: Results from the LURIC and 4D studies. J Am Soc Nephrol.2015; 26(9): 2213–21.
Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis IJC, 2015; 182: 168–170.
Banerjee A.Renal physiology. In: Clinical physiology an examination primer. USA, Cambridge University Press, 2005; 61.
Ricke L. Peran analisa urine pada penanganan penyakit ginjal dan traktus urinarius. Majalah Kedokteran Nusantara, 2012; 45(3): 167-76.
Johnson RJ, Kang D-H, Feig D, Kivlighn S, KanellisJ, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension, 2003; 41(6):1183–90.
Cain L, Shankar A, Ducatman AM, Steenland K. The relationship between serum uric acid and chronic kidney disease among Appalachian adults. Nephrol Dial Transplant, 2010; 25(11): 3593-9.
Dharma PS. Penyakit ginjal deteksi dini dan pencegahan. Yogyakarta, CV Solusi Distribusi, 2014; 1-11.
Hidayati T, Kushadiwijaya H, Suhardi. Hubungan antarahipertensi, merokok dan minuman suplemen energi dan kejadian penyakit ginjal kronis. Berita Kedokteran Masyarakat, 2008; 24(2): 90-102.
PERNEEFRI. 5th Report of Indonesian Renal Registry. Jakarta, Perhimpunan Nefrolog Indonesia, 2012; 1-40.
Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, et al. Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link?. J Am Soc Nephrol, 2005; 16: 1909–19. doi:10.1681/ASN.2005010063.
Gulati S. Chronic kidney disease. Int Urol Nephrol, 2010; 42(4): 1055-62.
Kliegman RM. Chronic kidney disease. Nelson textbook of pediatrics. 18thEd., Philadelphia, Elsevier/Saunders, 2007; 535: 2.
Nugroho SHP. Hubungan frekuensi konsumsi suplemen energi dengan stadium chronic kidney disease di ruang hemodialisis RSUD Ibnu Sina Gresik. J Surya, 2015; 07(01): 54-9.
Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, et al. Relationship of Plasma Galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. JAHA 2010; 1:e000760 doi:10.1161/JAHA.112.000760.
Suthahar N, Meijers WC, Sillje HHW, Ho JE, Liu F-T, deBoer RA. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An update. Theranostics, 2018; 8(3): 593-609.
Dickerson VM, Rissi DR, Brown CA, Brown SA, Schmiedt CW. Assessment of acute kidney injury and renal fibrosis after renal ischemia protocols in cats. The American Association for Laboratory Animal Science, 2017; 67(1): 56–66.
Suryawan DGA, Arjani IAMS, Sudarmanto IG. Gambaran kadar ureum dan kreatinin serum pada pasien gagal ginjal kronis yang menjalani terapi hemodialisis di RSUD Sanjiwani Gianyar. Meditory, 2016; 4(2): 145-53.
Amin N, Mahmood R, Asad M, Zafar M, Raja A. Evaluating urea and creatinine levels in chronic renal failure pre and post dialysis: A prospective study. JCVD, 2014; 2(2): 1-4.
Gaedeke J. Renal function test. In Laboratory and diagnostic test handbook. New York, Academic Press Inc, 2000; 706-15.
Islam N, Jahan SS, Badrudduza S, Hossain Z. Evaluation of primary screening test for platelet homeostasis in patients with chronic kidney disease. Bangladesh Journal of Medicine, 2012; 21(2): 55-57.
Gbinigie O, Price CP, Heneghan C, Van den Bruel A, Plüddemann A. Creatinine point-of-care testing for detection and monitoring of chronic kidney disease: primary care diagnostic technology update. Br J Gen Pract, 2015; 65(640): 608-9.
Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, et al. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol, 2011; 300(1): F245–53.
O'Seaghdha CM, Hwang S-J, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol, 2013; 24(9): 1470–7.
Tan R, Liu X, Wang J, Lu P, Han Z, Tao J, et al. Alternations of galectin levels after renal transplantation. Clin. Biochem, 2014; 47(15): 83–8.
Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, et al. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int, 2018; 93(1): 252–259.
Song G, Sun H, Han P, Ge N, Wang W, Yi T, Li S. Increased serum galectin-3 levels are associated with the development of type 2 diabetib nephropathy: A novel marker for progression?. Int J Clin Exp Med, 2018; 11(7): 7156-64.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension, 2001; 38(5): 1101–6.
Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion link macrophages to the promotion of renal fibrosis. AJP, 2008; 172(2): 288–98.
de Boer RA, Voors AA, Muntendam P, Van Gilst WH, Van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail, 2009; 11(9): 811–7.
Astor BC, Hallan SI, Miller IIIER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the U.S. Population. Am J Epidemiol, 2008; 167(10): 1226–34.
Mok Y, Lee JS, Kim MS, Wenying C, Young M, Sun HJ. Serum uric acid, and chronic kidney disease: The severance cohort study. Nephrol Dial Transplant, 2012; 27(5): 1831–5.
Opotowsky AR, Baraona F, Owumi J, Loukas B, Singh MN, Valente AM, et al . Galectin-3 is elevated and associated with adverse outcomes in patients with single-ventricle fontan circulation. J Am Heart Assoc, 2016; 5(1): e002706.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 1970 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
